Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GT Biopharma (GTBP) Net Income (2016 - 2021)

GT Biopharma (GTBP) has disclosed Net Income for 12 consecutive years, with -$18.2 million as the latest value for Q4 2021.

  • On a quarterly basis, Net Income fell 219.55% to -$18.2 million in Q4 2021 year-over-year; TTM through Dec 2021 was -$58.2 million, a 3227.4% decrease, with the full-year FY2025 number at -$12.4 million, up 11.0% from a year prior.
  • Net Income was -$18.2 million for Q4 2021 at GT Biopharma, down from -$5.9 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of $15.2 million in Q4 2020 to a low of -$235.8 million in Q3 2018.
  • A 5-year average of -$26.0 million and a median of -$5.1 million in 2017 define the central range for Net Income.
  • Peak YoY movement for Net Income: crashed 3538.46% in 2017, then skyrocketed 1135.65% in 2020.
  • GT Biopharma's Net Income stood at -$4.6 million in 2017, then tumbled by 5053.73% to -$235.8 million in 2018, then surged by 99.38% to -$1.5 million in 2019, then surged by 1135.65% to $15.2 million in 2020, then plummeted by 219.55% to -$18.2 million in 2021.
  • Per Business Quant, the three most recent readings for GTBP's Net Income are -$18.2 million (Q4 2021), -$5.9 million (Q3 2021), and -$4.4 million (Q2 2021).